Skip to main content

IL-23

      Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.
      New GRAPPA 2021 PsO and PsA Treatment Recommendations by Dr. Rachel Tate ( @uptotate)

      The evidence-based recommendation

      Dr. John Cush RheumNow

      4 years ago
      New GRAPPA 2021 PsO and PsA Treatment Recommendations by Dr. Rachel Tate ( @uptotate) The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021. Read more... https://t.co/AnHQGA8aKs https://t.co/4c18j4h54T
      Video: Personalization of PsA Treatment: Dr. Robert Chao ( @doctorRBC)

      Dr. Robert Chao reviews a talk given by Dr. Lau

      Dr. John Cush RheumNow

      4 years ago
      Video: Personalization of PsA Treatment: Dr. Robert Chao ( @doctorRBC) Dr. Robert Chao reviews a talk given by Dr. Laura Coates entitled, "Towards personalized treatment strategies for psoriatic arthritis", presented #EULAR2021. https://t.co/LeocvUyZ7N https://t.co/g6ApPL0Pui
      It seems like every conference we are presented with data on the newest biologic for treatment of psoriatic arthritis, but the question is, do we need it? Oral presentation (6937) discussed that issue and addressed our need for a more personalized approach to the treatment of PsA. 
      RT @Yuz6Yusof: No clear winner here. The majority would use #IL23 inhibitors as either 2nd or 3rd line bDMARDs and for #

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 years ago
      No clear winner here. The majority would use #IL23 inhibitors as either 2nd or 3rd line bDMARDs and for #psoriaticarthritis with severe #psoriasis. Thank you for participating in the polls #EULAR2021 @RheumNow https://t.co/b8wzaRVTqw
      EULAR 2021 - Day 2 Podcasts

      Check out this compilation of our EULAR 2021 Day 2 broadcasts below.

      You can also follow t

      Dr. John Cush RheumNow

      4 years ago
      EULAR 2021 - Day 2 Podcasts Check out this compilation of our EULAR 2021 Day 2 broadcasts below. You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud. https://t.co/GskToSkfLk https://t.co/nF2FkHgBtu
      RT @uptoTate: Poster #POS1031 pooled VOYAGE 1&2 and DISCOVER 1&2, GI-related SAE rates low. No uveitis, opportun

      Dr. Rachel Tate uptoTate

      4 years ago
      Poster #POS1031 pooled VOYAGE 1&2 and DISCOVER 1&2, GI-related SAE rates low. No uveitis, opportunistic infections, or new onset/exacerbation of IBD in GUS-treated pts. No new safety concerns were identified through 1-year follow up. #EULAR2021 @RheumNow https://t.co/7NxeOu6FLW
      RT @AurelieRheumo: COSMOS study: Guselkumab RCT in PsA pts TNFi-resistants (1 or 2) 44.4% of GUS vs 19.8% of PBO pts ach

      Aurelie Najm AurelieRheumo

      4 years ago
      COSMOS study: Guselkumab RCT in PsA pts TNFi-resistants (1 or 2) 44.4% of GUS vs 19.8% of PBO pts achieved ACR20 at w24 (p<0.001) and GUS > PBO for most secondary endpoints. Tolerance: 18% vs. 20% infections/SI. #OP0230 @Rheumnow #EULAR2021 @DrLauraCoates https://t.co/fFle2OR8KM
      RT @MeralElRamahiMD: 2021 GRAPPA STRONG recs (cont'd):
      *⃣Crohn's Dz &amp; UC: TNFi (not ETN), IL12/23i
      🚫strong rec

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years ago
      2021 GRAPPA STRONG recs (cont'd): *⃣Crohn's Dz & UC: TNFi (not ETN), IL12/23i 🚫strong rec against IL17i 2021 GRAPPA CONDITIONAL recs for: *⃣ Uveitis: TNFi (not ETN), CyA *⃣ Crohn's Dz & UC: IL23i, JAKi, MTX OP0229 #EULAR2021 @RheumNow https://t.co/AWyKqSapWG
      RT @MeralElRamahiMD: 2021 GRAPPA STRONG recs: *⃣Axial PsA/arthritis, biologic-naive or IR: TNFi, IL17i, JAKi*⃣Peri

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years ago

      2021 GRAPPA STRONG recs: *⃣Axial PsA/arthritis, biologic-naive or IR: TNFi, IL17i, JAKi *⃣Peripheral arthritis biologic-IR: above + IL23i *⃣Peripheral arthritis DMARD-IR: above + IL12/23i *⃣Peripheral arthritis DMARD-naive: above + PDE4i + csDMARD OP0229 #EULAR2021 @RheumNow https://t.co/Z2Nv073yoU

      RT @doctorRBC: Risankizumab (IL-23i) phase III trial for PsA inadequate response to biologic
      ⭐️ACR20, 50,70 response

      Robert B Chao, MD doctorRBC

      4 years ago
      Risankizumab (IL-23i) phase III trial for PsA inadequate response to biologic ⭐️ACR20, 50,70 response ⭐️significant resolution of enthesitis/dactylitis Abs#OP0228 #EULAR2021 @RheumNow
      ×